Purchase Order 75N91018P00753

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $4,470.04 on April 6, 2018, with completion on June 22, 2019. Work was performed in Bethesda, Maryland. The order carried firm fixed price and no set-aside designation. The source does not specify the items or services procured.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $5,611.84 on July 11, 2017, with ultimate completion on August 16, 2018. No set-aside was used. Performance occurs in Bethesda, Maryland. The order is for laboratory instrumentation, reagents, consumables, or maintenance services typical of Life Technologies' federal portfolio in life-sciences research and diagnostic infrastructure. Pricing is firm fixed price.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for lab equipment valued at $24,628.60 on September 22, 2020, with completion on December 22, 2020. Performance takes place in Bethesda, Maryland. The order is firm fixed price with no small business set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation valued at $24,898.13 on August 30, 2018, with ultimate completion on August 29, 2019. No set-aside category applied. Place of performance is Bethesda, Maryland. The purchase order uses fixed-price pricing with economic price adjustment. Life Technologies operates as Thermo Fisher Scientific and supplies laboratory instrumentation, reagents, and consumables to federal research and diagnostic programs.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $20,776.50 on September 5, 2019, with completion by October 5, 2019. Place of performance is Carlsbad, California. The order represents a firm fixed-price, commercial purchase of laboratory instrumentation, reagents, or consumables—Life Technologies' core federal offering in genetic analysis and molecular biology. No set-aside was applied.</p>

The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $13,275.12 on September 12, 2019, with completion by September 18, 2020. The order is for maintenance services, using fixed-price pricing with economic price adjustment and carries no small business set-aside. Performance takes place in Bethesda, Maryland. Life Technologies operates as Thermo Fisher Scientific and supplies laboratory instrumentation, reagents, and maintenance services across federal...

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $13,879.50 in biological kits, with an award date of June 13, 2019 and completion date of July 13, 2019. Place of performance is Carlsbad, California. The order is priced on a firm fixed price basis with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for biologicals valued at $13,401.67 on March 12, 2020, with an ultimate completion date of April 9, 2020. Place of performance is Bethesda, Maryland. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $14,621.46 on November 20, 2019, with an ultimate completion date of December 19, 2019. The order procures drugs and biologicals on a firm fixed-price basis. Place of performance is Grand Island, New York.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation on August 5, 2015, valued at $3,011.04 for scientific instruments, reagents, or consumables with a firm fixed price structure. Performance occurred in Baltimore, Maryland, with an ultimate completion date of September 28, 2016. No set-aside applied to this simplified acquisition.</p>